MX9301336A - Compuestos novedosos. - Google Patents
Compuestos novedosos.Info
- Publication number
- MX9301336A MX9301336A MX9301336A MX9301336A MX9301336A MX 9301336 A MX9301336 A MX 9301336A MX 9301336 A MX9301336 A MX 9301336A MX 9301336 A MX9301336 A MX 9301336A MX 9301336 A MX9301336 A MX 9301336A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- novelty
- fludzinski
- trifluor
- indole
- Prior art date
Links
- -1 1,2-Dimethyl-3-ethyl-1H-indole-5-yl Chemical group 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929205422A GB9205422D0 (en) | 1992-03-12 | 1992-03-12 | Novel compounds |
| GB929205442A GB9205442D0 (en) | 1992-03-12 | 1992-03-12 | Novel compounds |
| GB929205416A GB9205416D0 (en) | 1992-03-12 | 1992-03-12 | Novel compounds |
| GB929205415A GB9205415D0 (en) | 1992-03-12 | 1992-03-12 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9301336A true MX9301336A (es) | 1993-10-01 |
Family
ID=27450844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9301336A MX9301336A (es) | 1992-03-12 | 1993-03-10 | Compuestos novedosos. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5508288A (enExample) |
| EP (1) | EP0630373A1 (enExample) |
| JP (1) | JPH07504429A (enExample) |
| MX (1) | MX9301336A (enExample) |
| TW (1) | TW234125B (enExample) |
| WO (1) | WO1993018028A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014801A1 (en) * | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
| GB9302275D0 (en) * | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
| GB9306460D0 (en) * | 1993-03-29 | 1993-05-19 | Smithkline Beecham Plc | Novel compounds |
| GB9308802D0 (en) * | 1993-04-28 | 1993-06-09 | Smithkline Beecham Plc | Treatment |
| GB9420521D0 (en) * | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
| GB9511355D0 (en) * | 1995-06-06 | 1995-08-02 | Fujisawa Pharmaceutical Co | Urea derivatives |
| WO1998047868A1 (en) * | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
| US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US6344476B1 (en) * | 1997-05-23 | 2002-02-05 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
| GB9719530D0 (en) * | 1997-09-12 | 1997-11-19 | Smithkline Beecham Plc | Novel compounds |
| GB9724372D0 (en) | 1997-11-18 | 1998-01-14 | Smithkline Beecham Plc | Novel compounds |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| ID26620A (id) * | 1997-12-22 | 2001-01-25 | Bayer Ag | Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi |
| US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| AU2006201959B2 (en) * | 1997-12-22 | 2008-09-04 | Bayer Healthcare Llc | Inhibition of Raf Kinase using Substituted Heterocyclic Ureas |
| US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| US8124630B2 (en) * | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| AU2002351196A1 (en) * | 2001-12-03 | 2003-06-17 | Bayer Pharmaceuticals Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| ES2378670T3 (es) * | 2002-02-11 | 2012-04-16 | Bayer Healthcare, Llc | Aril ureas como inhibidores de cinasas |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| PL1626714T3 (pl) | 2003-05-20 | 2007-12-31 | Bayer Healthcare Llc | Diarylowe pochodne mocznika do schorzeń, w których pośredniczy PDGFR |
| CA2532865C (en) * | 2003-07-23 | 2013-08-06 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the inhibition of kinase signaling |
| CA2555720A1 (en) * | 2004-02-26 | 2005-09-09 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Isoquinoline derivatives |
| AU2006204790B2 (en) * | 2005-01-14 | 2012-08-23 | Gilead Connecticut, Inc. | 1,3-diaryl substituted ureas as modulators of kinase activity |
| US7777040B2 (en) * | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| EP1910297B1 (en) * | 2005-07-11 | 2016-05-25 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| TWI340607B (en) | 2005-08-12 | 2011-04-11 | Au Optronics Corp | Organic electroluminescent display panel and fabricating method thereof |
| WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| CA2905089C (en) | 2013-03-15 | 2023-06-13 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds for the treatment of ocular diseases |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| WO2017086941A1 (en) | 2015-11-17 | 2017-05-26 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Alcon Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| EP3849555A4 (en) | 2018-09-14 | 2022-05-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992005170A1 (en) * | 1990-09-13 | 1992-04-02 | Beecham Group Plc | Indole ureas as 5 ht receptor antagonist |
-
1993
- 1993-03-04 WO PCT/GB1993/000449 patent/WO1993018028A1/en not_active Ceased
- 1993-03-04 EP EP93905507A patent/EP0630373A1/en not_active Withdrawn
- 1993-03-04 US US08/295,694 patent/US5508288A/en not_active Expired - Fee Related
- 1993-03-04 JP JP5515449A patent/JPH07504429A/ja active Pending
- 1993-03-10 MX MX9301336A patent/MX9301336A/es unknown
- 1993-03-11 TW TW082101800A patent/TW234125B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07504429A (ja) | 1995-05-18 |
| US5508288A (en) | 1996-04-16 |
| TW234125B (enExample) | 1994-11-11 |
| WO1993018028A1 (en) | 1993-09-16 |
| EP0630373A1 (en) | 1994-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9301336A (es) | Compuestos novedosos. | |
| CU23393A3 (es) | Compuestos inhibidores de la raf kinasa y composiciones farmacéuticas que los contienen | |
| ECSP941156A (es) | 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines | |
| AR002705A1 (es) | Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen. | |
| ES2135414T3 (es) | Antagonistas del receptor 5-ht4. | |
| ATE88998T1 (de) | Benzodiazepin-derivate und diese enthaltende arzneimittel. | |
| MX19448A (es) | Procedimiento para la prreparacion de compuestos antagonistas de los receptores de aminoacidos excitadores; compuestos obtenidos y composicion farmaceutica que los incluye. | |
| ATE106401T1 (de) | Benzodiazepin-analoge. | |
| KR900700465A (ko) | 화합물 | |
| ES2097448T3 (es) | Sulfitos y sulfatos ciclicos de fructopiranosis con actividad anticonvulsiva. | |
| UA27776C2 (uk) | Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців | |
| BR9913319A (pt) | Composições e métodos para tratamento de doenças mitocondriais | |
| NO983749L (no) | CCR-3 reseptor-antagonister | |
| PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
| ES2094792T3 (es) | Uso de compuestos con actividad agonista de receptor 5-ht1a para la inhibicion de la secrecion de acidos gastricos. | |
| SE9702564D0 (sv) | New compounds | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| MX9300616A (es) | Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene | |
| MX9301197A (es) | Derivados de indol. | |
| ES2021807B3 (es) | Mecanismo para el apoyo elastico de carriles de broca | |
| BR9507771A (pt) | Processos para preparação de ácido 1-Butil-2-(2'-(2H-Tetratozol-5-IL)-Bifenil-4-Ilmetil(-1H-Indol-3-Carboxílico | |
| MX9201324A (es) | Nuevos compuestos para inhibir la secrecion acida gastrica en mamiferos, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| ES2161718T3 (es) | 2,5-dioxo-2,5-dihidro-1h-benzo(b)azepinas como antagonistas de los receptores de nmda. | |
| MX9304424A (es) | Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
| GT199800203A (es) | Compuestos de triazina. |